RxDoctor Payments Data

Michael Dollard, PA

Physician Assistant · Slingerlands, NYNPI 1194788372

Payments from drug & device makers

$760in general payments, 2019–2025

Across 19 payments — averaging $40.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$360
  • GSK$125
  • Amgen$112
  • Biohaven Pharmaceuticals, Inc.$41
  • Novo Nordisk$40
  • Pfizer$35
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca6$360
GSK2$125
Amgen1$112
Biohaven Pharmaceuticals, Inc.3$41
Novo Nordisk2$40
Pfizer2$35
AbbVie2$31
Vertex1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$760 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$28,129
Medicare patients
89
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$90,198
FarxigaDapagliflozin Propanediol46$44,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$38,681
EliquisApixaban40$37,338
JardianceEmpagliflozin32$32,298
OxycontinOxycodone Hcl26$27,536
TradjentaLinagliptin30$26,931
MounjaroTirzepatide16$17,233
LinzessLinaclotide27$16,929
JanuviaSitagliptin Phosphate18$16,727
Breo ElliptaFluticasone/Vilanterol18$12,284
Tresiba Flextouch U-200Insulin Degludec11$6,364
MyrbetriqMirabegron11$5,864
Varenicline Tartrate32$5,804
Spiriva HandihalerTiotropium Bromide11$5,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$90,19863 claims
GSKTrelegy Ellipta, Breo Ellipta$125$50,96576 claims
AstraZenecaFarxiga, Brilinta$360$49,56057 claims
PfizerEliquis$35$37,33840 claims
AbbVieLinzess$31$16,92927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Slingerlands

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →